BMO Capital initiated coverage of LifeStance (LFST) with an Outperform rating and $8 price target With new initiatives in place to boost growth, attention has turned to their effectiveness, the analyst tells investors in a research note. LifeStance’s focus is shifting from solely adding clinicians to also enhancing their productivity, while expanding into specialty care offers additional upside, the firm says, adding that the stock appears attractively valued.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LFST:
- Positive Outlook for LifeStance Health Group: Overcoming Challenges and Driving Growth with Strategic Initiatives
- Strong Performance and Promising Outlook: Richard Close Reaffirms Buy Rating for Lifestance Health Group
- LifeStance price target raised to $10 from $9 at UBS
- LifeStance Health Group Reports Strong Q3 2025 Results
- LifeStance Health’s Earnings Call: Strong Growth Amid Challenges